Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2024-03-13 Capital/Financing Update
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo har framgångsrikt emitterat seniora säkerställda sociala obligationer med rörlig ränta om SEK 500 m och offentliggör resultatet av återköpserbjudandet avseende sina befintliga obligationer
Capital/Financing Update Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and details a significant corporate financial action: the successful issuance of SEK 500 million in new senior secured social bonds and the results of a tender offer to repurchase existing bonds. This clearly falls under corporate financing activities, specifically related to debt issuance and capital structure management. Based on the provided definitions, the most appropriate category is 'Capital/Financing Update' (CAP). Although it is a press release, the core content is the financing event itself, not just an announcement of a report (which would suggest RPA or RNS). The document is comprehensive regarding the financing terms and results.
2024-03-13 Swedish
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is titled "Delårsrapport kv 4 2023, inkl. bokslutskommuniké" (Interim Report Q4 2023, including year-end press release) and contains detailed financial tables covering Q4 2023 and the full year 2023 (jan-dec). It includes key performance indicators, segment results (US Pharma), cash flow, and management commentary on financial performance and outlook. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year (Q4/Half-year/Nine-month report), which aligns with the definition of an Interim/Quarterly Report (IR). Although it includes a 'bokslutskommuniké' (year-end press release), the overall document is a detailed interim financial report, not just the initial earnings release (ER) or the full Annual Report (10-K). Q4 2023
2024-02-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report Q4 2023, incl. Full Year Report' and contains detailed financial statements, including income statements, balance sheet data, and management commentary on financial performance. It provides comprehensive financial results for the period, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement, as it contains the full report content. Q4 2023
2024-02-08 English
Investor Presentation 2023
Investor Presentation Classification · 1% confidence The document is titled "Delårsrapport kv 3 2023" (Interim Report Q3 2023) and contains detailed financial tables comparing Q3 2023 results with previous periods (Q3 2022, YTD 2023, YTD 2022, FY 2022). It includes key performance indicators like net sales, EBITDA, EBIT, and cash flow, along with management commentary on business segments (US Pharma) and product pipeline updates (OX124, MODIA). This structure and content are characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it classifies as an Interim / Quarterly Report.
2023-11-02 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'Q3 2023 Interim Report' and contains comprehensive financial data, including income statements, cash flow analysis, and management commentary on quarterly performance. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2023
2023-11-02 English
Kommuniké från Orexo:s extra bolagsstämma
AGM Information Classification · 1% confidence The document is titled "Kommuniké från Orexo:s extra bolagsstämma" (Communiqué from Orexo's Extraordinary General Meeting). It details decisions made regarding the election of a new board member (Robin Evers) and the remuneration for the board following the vote. This content directly relates to the outcomes of a shareholder meeting and the composition/governance of the board. The most fitting category is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) functions similarly to an AGM in terms of voting on board composition, and the document is a summary/communiqué of the results. While DVA (Declaration of Voting Results) is related, AGM-R is often used for the official summary materials released immediately following such meetings, especially when board changes are involved. Given the focus on board changes and remuneration decisions made at the meeting, AGM-R is the primary classification.
2023-10-26 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.